LOGIN  |  REGISTER
Astria Therapeutics
Cue Biopharma

Bio-Techne Ends Collaboration Program With Akoya To Automate RNAscope On The Phenocycler Fusion

August 14, 2023 | Last Trade: US$75.84 5.10 7.21

MINNEAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that the company will end their collaboration with Akoya Biosciences to co-develop an automated RNAscope™ workflow for use with the PhenoCycler®-Fusion System. The decision was made following best efforts to achieve the intended program goals.

"Bio-Techne remains focused on providing the greatest value to the spatial biology community," said Kim Kelderman, President of Bio-Techne's Diagnostics and Genomics Segment. "We are actively expanding the capabilities of our gold-standard RNAscope technology to enable greater utility in multiomic spatial applications and plan to accelerate the development and commercialization of the first fully automated and scalable spatial multiomics workflow on the Lunaphore COMET™ system."

Bio-Techne will continue to support its customers utilizing RNAscope assays in conjunction with Opal™ reagents and PhenoImager™ HT systems purchased from Akoya.

About Bio-Techne Corporation

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2023 and has approximately 3,200 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

Bio-Techne Investor Contact:
David Clair,
Vice President, Investor Relations and Corporate Development
612-656-4416
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Astria Therapeutics

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB